The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Comparing Two Types of Obesity Surgeries: Which Is Better?
March 6th 2015Study results show that patients who underwent Roux-en-Y gastric bypass surgery experienced greater and more rapid weight loss at 12- and 24 months post-surgery compared to patients who received the sleeve gastrectomy procedure. GB patients also experienced a larger decrease in hemoglobin within the first two months post-surgery and a sustained decrease in creatinine.
Kidney Disease Risk Higher with Longer Exposure to Antiretrovirals, Study Finds
March 1st 2015Chronic kidney disease developed in association with exposure to antiretrovirals in people with initially normal levels of estimated glomerular filtration rate (eGFR) was not limited to increased incidence immediately after starting therapy but in fact increased over time and exposure.
New Formulation Compares Favorably to Current, Commonly Used Tenofovir Dose
March 1st 2015Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.
Combo Drug Shows High Hepatitis C Cure Rates in Patients Coinfected with HIV
March 1st 2015An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
PrEP for HIV Prevention: Where We Are and Where Do We Need to Go?
Pre-exposure prophylaxis (PrEP) is a strategy with significant historical precedent in the infectious disease field. Applied to HIV prevention, at-risk individuals would take PrEP to protect against HIV acquisition in case of any planned or unplanned exposure, potentially permitting HIV prophylactic control by the uninfected individual.
ALLY-2 Results: Near Total Hepatitis C-HIV Cure Rate
Bristol-Myers Squibb today announced that its Phase III clinical trial of a combination product daclatasvir-sofosbuvir showed dramatic cure rates for patients infected with both HIV and Hepatitis C. The results of the trial, known as ALLY-2, were presented at the 2015 Conference on Retroviruses and Opportunistic Infections in Seattle, WA.
Hepatitis C Challenges and Successes in the Era of Interferon-Free Treatment
February 26th 2015Today, there are multiple combinations of interferon-free treatments that have efficacy rates of 90% or higher and are better tolerated with fewer severe side effects than previous interferon-based therapies.
Experimental Ebola Drug May Be Effective in Patients in Early Stage of Disease
February 25th 2015Favipiravir, an experimental drug to treat the deadly Ebola virus, appeared to help some patients in Guinea with the disease but not others, according to results of the trial released at the 2015 Conference on Retroviruses and Opportunistic Infections held this week in Seattle.
Study Says HIV Care Dropped in Face of Ebola Outbreak
February 25th 2015The Ebola virus epidemic in West Africa led to a decline in the number of people seeking general outpatient services and as a result caused a drop in HIV testing and enrollment of new patients who are HIV positive, a new study suggests.
Tiotropium Improves Lung Function, Regardless of Allergic Status, Study Reports
Adding tiotropium Respimat treatment in adult patients with mild, moderate, and severe asthma who continue to experience symptoms despite the use of maintenance therapies significantly improved lung function, according to a presentation by Boehringer Ingelheim scientists at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Houston, TX.